Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-03
2006-10-03
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07115631
ABSTRACT:
In one aspect, the present invention is directed to methods for treating fatigue, neurobehavioral slowing and other cognitive disorders and defects due to cancers and treatments associated with cancers, and similar conditions. In a further aspect, the present invention is directed to methods for treating disorders related to menopause, including executive function defects. The methods involve the administration of a composition comprising D-threo methylphenidate that is substantially free of L-threo methylphenidate and of erythro forms of methylphenidate.
REFERENCES:
patent: 2507631 (1950-05-01), Hartman et al.
patent: 2957880 (1960-10-01), Rometsch
patent: 4137300 (1979-01-01), Sheth et al.
patent: 4992445 (1991-02-01), Lawter et al.
patent: 5104899 (1992-04-01), Young et al.
patent: 5114946 (1992-05-01), Lawter et al.
patent: 5217718 (1993-06-01), Colley et al.
patent: 5283193 (1994-02-01), Yamamoto et al.
patent: 5284769 (1994-02-01), Evans et al.
patent: 5331000 (1994-07-01), Young et al.
patent: 5362755 (1994-11-01), Barberich et al.
patent: 5375693 (1994-12-01), Woosley et al.
patent: 5449743 (1995-09-01), Kobayashi et al.
patent: 5733756 (1998-03-01), Zeitlin et al.
patent: 5773478 (1998-06-01), Richards et al.
patent: 5837284 (1998-11-01), Mehta et al.
patent: 5874090 (1999-02-01), Baker et al.
patent: 5908850 (1999-06-01), Zeitlin et al.
patent: 6031124 (2000-02-01), Fox et al.
patent: 6113879 (2000-09-01), Richards et al.
patent: 6127385 (2000-10-01), Midha et al.
patent: 6221883 (2001-04-01), Baldessarini et al.
patent: 6242464 (2001-06-01), Harris et al.
patent: 6344215 (2002-02-01), Bettman et al.
patent: 6355656 (2002-03-01), Zeitlin et al.
patent: 6395752 (2002-05-01), Midha et al.
patent: 6441178 (2002-08-01), Zavareh et al.
patent: 6468504 (2002-10-01), Richards et al.
patent: 6486177 (2002-11-01), Zeldis et al.
patent: 6531489 (2003-03-01), Harris et al.
patent: 2002/0019535 (2002-02-01), Zavareh et al.
patent: 2002/0032335 (2002-03-01), Langston et al.
patent: 2003/0049205 (2003-03-01), Richards et al.
patent: 2003/0105134 (2003-06-01), Harris et al.
patent: 2 376 215 (2001-12-01), None
patent: 2 223 643 (2003-12-01), None
patent: 0 885 191 (2002-01-01), None
patent: 0 889 874 (2002-01-01), None
patent: 0 841 928 (2002-09-01), None
patent: 0 879 228 (2002-10-01), None
patent: 0 958 281 (2004-03-01), None
patent: 589625 (1945-01-01), None
patent: 788226 (1957-12-01), None
patent: 878167 (1961-09-01), None
patent: 466229 (1975-04-01), None
patent: 96/41617 (1996-12-01), None
patent: WO 97/03671 (1997-02-01), None
patent: WO 97/03672 (1997-02-01), None
patent: WO 97/03673 (1997-02-01), None
patent: WO 97/27176 (1997-07-01), None
patent: WO 97/28124 (1997-08-01), None
patent: WO 97/32851 (1997-09-01), None
patent: WO 97/35836 (1997-10-01), None
patent: WO 98/23263 (1998-06-01), None
patent: WO 98/25902 (1998-06-01), None
patent: WO 98/31668 (1998-07-01), None
patent: WO 00/74680 (2000-12-01), None
patent: WO 01/43730 (2001-06-01), None
Angrist, et al.,J. Clinical Psychopharmacology,1992, 12(4), 268-272.
Barkley, et al,Pediatrics,1990, 86(2), 184-192.
Barkley, et al.,Pediatrics,1991, 87(4), 519-531.
Golinko,Prog. Neuro-Psychopharmacol&Biol. Psychiat.,1984, 8, 1-8.
Green,Pediatric Psychopharmacology,1992, 15(1), 1-27.
Holmes, et al., “Psychostimulant response in aids-related complex patients,”J. Clin. Psychiatry,1989, 50(1), Biosis Abstract No. 87129969, 1989, 5-8.
Scott, “Stereoisomers and drug toxicity,”Drug Safety,1993, 8(2), 149-159.
Srinivas, et al., “Enantioselective pharmacolinetics and pharmacodynamics of racemic threo-methylphendiate in children with attention deficite hyperactivity disorder,”Clin. Pharmacol. Ther.,Biois Abstract No. 95066168, 1992, 52(5), 561-568.
White, et al., “Methylphenidate as a treatment for depression in acquired immunodeficiency syndrome: an n-of-1 trial,”J. Clin. Psychiatry,1992, 53(5), 153-156.
Aoyama, et al., “Pharmacolinetics and pharmacodynamics of (=)-threo-methylphenidate enantiomer in patients with hypersomjnia,”Clin. Pharmacol. Ther.,1994, 55(3), 270-276.
Bowden, K., et al., “Reactions of carbonyl compounds in basic solutions, Part 15. The alkaline hydrolysis of N-methyl, N-phenyl, and bicyclo lactams, penicillins, and N-alkyl-n-methylacetamides,”J. Chem. Soc. Perkin Trans.,1990, 2(12), 2111-2116.
Brown C., “Pharmacological action and drug development,” Chirality in Drug Design and Synthesis,Academic Press Inc.,1990, 4-7.
Brown, G., “The use of methylphenidate for cognitive decline associated with HIV disease,”Intl. J. Psych. Med.,1995, 25(1), 21-37.
Corey, et al., “A new synthetic approach to the penicillins,”J. Amer. Chem. Soc.,1965, 87(11), 2518-2519.
Ding, L.K., et al., “Cis- and trans-azetidin-2-ones from nitrones and copper acetylide,”J. Chem. Soc. Perkin I,1976, 22, 2382-2386.
Douzenis, et al., Phychiatric disorder in HIV disease: description of 200 referrals to a liaison psychiatry service,Proc. 7thInt'l conf. AIDS,1991, 1, 2135-2215.
Earle, et al., “Synthesis and hydrolysis of some fused-ring β-lactams,”J. Chem. Soc.,1969, 2092098.
Greehill, “Pharmacologic treatment of attention deficit hyperactivity disorder,”Pediatric Psychoparmacology,1992, 15(1), 1-27.
Greenhill, L., “Attention-deficit hyperactivity disorder child & adol.,”Psych. Clin. N.A.,1995, 4, 123-165.
Hou, J.P., et al., “Beta-lactam antibiotics: their physicochemical properties and biological activities in relation to structure,”J. Pharm. Sci.,1971, 60(4), 503-532.
Klibanov, A.M. “Asymmetric transformations catalyzed by enzyumes in organic solvents,”Acc. Chem. Res.,1990, 23, 114-120.
Moll, F., “Darstellung von 1-Asa-bicyclo [4.2.0]octan-2-on,”Naturforsch Teil B.,1966, 21, 297.
Navia, et al., “The AIDS dementia complex: I. Clinical features,”Annals of Neurology,1986, 19, 517-524.
Patrick, et al., “Pharmacology of the enantiomers of threo-methylphenidate,”J. Pharmacol. & Exp. Terhap.,1987, 241, 152-158.
Rieder, et al., “Diagnosis of sulfonamide hypersensitivity reactions by in-vitro “rechallenge” with hydroxylamine metabolites,”Ann. Intern. Med.,1989, 110, 286-289.
Srinivas, et al., “Enantiomeric gas chromatography assay with electron capture detection for d-ritalinic acid in plasma,”J. Chromatagraph,1990, 530, 327-336.
Srinivas, et al., “Sterioselective disposition of methylphenidate in children with attention deficit disorder,”J. Pharmacol. Exp. Ther.,1987, 241, 300-306.
Srinivas, et al., “Anantioselective pharmacokinetics of dl-threo-methylphenidate in humans,”Pharmacol Res.,1993, 10, 14-21.
Staal, et al., “Glutathione deficiency and human immunodeficiency virus infection,”Lancet,1992, 339, 909-912.
Uetrecht, et al., “Idiosyncratic drug reactions: possible role of reactive metabolites generated by leukocytes,”Pharmacol Res.,1989, 6, 265-273.
“Attention-deficit and disruptive behavior disorders: Attention-deficit/hyperactivity disorder,” American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders,Fourth ed.(DSM-IV) Washington, DC, 1994, 78-85.
Beck, A.T., et al., “Assessment of depression: the depression inventory,”Mod. Probl. Pharmacopsychiatry,1974, 7, 155-169.
Brown, T.E., “Attention deficit disorders and comorbidities in children adolescents and adults,”American Psychiatric Press, Washington, DC,2000, 40-41.
Bruera, E., et al., “Neuropsychological effects of methylphenidate in patients receiving a contiuous infusion of narcotics for cancer pain,”Pain,1992, 48, 163-166.
Cella, D.F., et al., “The functional assessment of cancer therapy scale: development and validation of the general measure,”J. Clin. Oncol.,1993, 11(3), 570-579.
Srinivas, N.R., et al., “Enantioselective pharmacoki
Dariani Maghsoud M.
Faleck Herbert J.
Khetani Vikram
Sterling David
Zeitlin Andrew L.
Celgene Corporation
Henley, III Raymond J
Woodcock & Washburn LLP
LandOfFree
Methods for treatment of cognitive and menopausal disorders... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treatment of cognitive and menopausal disorders..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment of cognitive and menopausal disorders... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3679079